WASHINGTON — Sens. Elizabeth Warren (D-Mass.) and Bill Cassidy (R-La.) want Congress to take a deeper look at how Biogen’s controversial and pricey new Alzheimer’s drug, Aduhelm, will affect the Medicare program, they wrote in a letter Wednesday.
The bipartisan duo is pressing the Senate Finance Committee to take on “the vexing new questions and challenges that approval raises for the Medicare program and other health programs” the panel oversees, they wrote.
Experts predict the drug could dramatically increase Medicare spending. If even just 500,000 of the 6.2 million seniors currently living with Alzheimer’s began taking Aduhelm, Medicare drug spending would balloon by $29 billion in one year, according to an estimate from the nonpartisan Kaiser Family Foundation.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
